Tigecycline Resistance among Clinical Isolates of Staphylococcus aureus from North-east India

Year 2017, Volume: 07 Issue: 04, 173 - 177, 15.12.2017

Swati Sharma Deepshikha Bhowmik Amitabha Bhattacharjee

https://doi.org/10.5799/jmid.368660

Abstract

Objective: The current study investigated the resistance against
cycline group of antibiotic among clinical isolates of Staphylococcus aureus and molecular characterization with special
reference to phenotypic screening of Tigecycline resistance.

Methods:
197 coagulase producing Staphylococcus spp. were collected from private
diagnostic laboratories and Silchar Medical College and Hospital, India.
Phenotypic screening was done with cycline groups of antimicrobials and
genotypically characterized by PCR, targeting coa gene. Detection of tetK,
tetM, tetO and tetX genes was
performed by PCR. Antibiogram profiling was performed and clonality was also
determined.

Results:
127 coagulase positive S. aureus were
phenotypically screened with cycline group of antibiotics in which prominent
resistant type showed highest non-susceptibility against Tigecycline 53.5%
(n=68) while lowest against minocycline 20.5% (n=26). Multiplex PCR assay
showed that tet(K) gene to be the
most common cycline group of antimicrobial resistance determinant in S. aureus, followed by tet(M) gene. Multiple genes were also
observed. However, resistant gene tet(O)
was not reported. Antibiotic susceptibility testing and MIC for therapeutic
purpose showed highest susceptibility rate against linezolid. DNA
fingerprinting experimented with PFGE had shown seven pulsotypes.

Conclusion: Resistance to
cycline group of antibiotics with special reference to Tigecycline is not
frequently reported from India. Thus, this study is of clinical interest in
terms of selection of proper antimicrobial chemotherapy and also using Tigecycline
for phenotypic screening of cycline group of antibiotic resistance in Staphylococcus aureus. 

Keywords

Tigecycline, tet genes, Staphylococcus aureus, North-east India

References

• 1. Scheinfeld N. Tigecycline: a review of a new glycylcycline antibiotic. J Dermatol Treatment 2005; 16: 207-212. 2. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599. 3. Hope R, Mushtaq S, James D, Pllana T, Warner M, Livermore DM. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK. J Antimicrob Chemother 2010; 65: 2602-2609. 4. Babu NGR, Shree GBB, Rekha L, Karthiga P. Molecular analysis of Coagulase (coa) gene polymorphism in clinical isolates of Staphylococcus aureus by PCR-RFLP. Int J Innov Res Sci Engin Technol 2014; 3: 8163-8168. 5. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B. Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 2009; 129: 446-450. 6. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260. 7. Costa AR, Batistao DWF, Ribas RM, Sousa AM , Pereira MO, Botelho CM. Staphylococcus aureus virulence factors and disease. Microbial pathogens and strategies for combating them: science, technology and education. Formatex 2013; 702-710. 8. Hookey JV, Richardson JF, Cookson BD. Molecular Typing of Staphylococcus aureus based on PCR Restriction Fragment Length Polymorphism and DNA Sequence Analysis of the Coagulase Gene. J Clin Microbiol 1998; 36: 1083-1089. 9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement M100-S24.CLSI, Wayne, PA, USA, 2014. 10. U. S. Food and Drug Administration. Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101 W10521C005 ET01 Rev 12/08. NDA 21-821/S-016: 3-21. 11. Duran N, Ozer B, Duran GG, Onlen Y, Demir C. Antibiotic resistance genes & susceptibility patterns in staphylococci. Indian J Med Res 2012; 135: 389-396. 12. Trzcinski K, Cooper BS, Hryniewicz W, Dowson CG. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2000; 45: 763-770. 13. Schmitz FJ, Krey A, Sadurski R, Verhoef J, Milatovic D, Fluit C. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J Antimicrob Chemother 2001; 47: 239-240. 14. Huys G, Haene KD, Eldere JV, Holy AV, Swings J. Molecular Diversity and Characterization of Tetracycline-Resistant Staphylococcus aureus Isolates from a Poultry Processing Plant. Appl Environm Microbiol 2005; 71: 574-579. 15. Bismuth R, Zilhao R, Sakamoto H, Guesdon JL, Courvalin P. Gene heterogeneity for tetracycline resistance in Staphylococcus spp. Antimicrob Agents Chemother 1990; 34: 1611-1614. 16. Shittu AO, Okon K, Adesida S, et al. Antibiotic resistance and molecular epidemiology of Staphylococcus aureus in Nigeria. BMC Microbiol 2011; 11: 92 17. Werner G, Gfrorer S, Fleige C, Witte W, Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008; 61:1182-1183.